Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Fabrice André
Multicentre validation of BRCAura, an AI-based histology model predicting germline BRCA1/2 mutations in HR+/HER2− breast cancer
Abstract Germline BRCA1/2 alterations (gBRCAm) are actionable drivers of breast cancer management, yet testing strategies based on clinical and family-history criteria miss many carriers. We developed BRCAura, a deep learning model that predicts gBRCAm status directly from routine histology whole-slide images.
Research Study Attrition and Participant-Informed Retention Strategies Among Cancer Survivors
|
Research Study Attrition and Participant-Informed Retention Strategies Among Cancer Survivors Supplement 1. eTable 1. Overall characteristics of the CANTO cohort eTable 2. Multivariable logistic regression models of factors associated with non-responsiveness at Y-4 and Y-6 eTable 3. Characteristics of participants that were excluded vs. included in the complete-case analyses at Y-4 and Y-6 because of missing baseline data eTable 4.
By Antonio Di Meglio, Camila Chiodi, Julie Havas, Elise M. Martin, Élise Martin, Martina Pagliuca, Mariam Chichua, Emma Gillanders, Guillemette Jacob, Aurélie Bertaut, Diane Boinon, Barbara Pistilli, Anne-Laure Martin, Sibille Everhard, Christelle Jouannaud, Courèche Guillaume Kaderbhai, Anne Kieffer, Olivier Tredan, Christelle Levy, Olivier Rigal, Matteo Lambertini, Stefan Michiels, Fabrice André, Gwenn Menvielle, Maria Alice Franzoi, Ines Vaz-Luis, Petya Zyumbileva, Pietro Lapidari, Romaine Desjardin, Aude Barbier
|
JAMA Network
Verified
Rb-driven transcription limits its tumour-suppressive effects in breast cancer
|
Abstract The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression1. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens2. How pharmacologically activated Rb remodels chromatin and influences transcription beyond cell cycle arrest remains poorly understood.
By April C. Watt, Antonio Ahn, Catherine Blyth, Julia Dixon-Douglas, Rhiannon Coulson, Michael Taylor, Keefe Chan, Catherine Dietrich, Brendan Russ, Susanne Ramm, Kun-Hui Lu, Nichelle Pires, Ching-Seng Ang, Mark Dawson, Elgene Lim, Monica Arnedos, Sarat Chandarlapaty, Fabrice André, Shom Goel, Krutika Ambani, Christabella A. Mahendra, Jesus Garcia-Sannicolas, Olivia Voulgaris, Sheena Nunag
|
Nature
Verified
118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)
Background Ribociclib demonstrated clinically and statistically significant progression-free survival (PFS) and overall survival (OS) benefits in 3 trials in patients with hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (MONALEESA -2, -3, -7). We present an exploratory analysis of the MONALEESA trials of first-line patients with long-term response (LTR; PFS >4 y) to ribociclib and first-line postmenopausal patients with very long-term response (VLTR; PFS >5 y).
Fabrice Andre | Authors | CancerNetwork
Articles by Fabrice Andre 118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS) ByFabrice Andre,Peter A. Fasching,Aleix Prat,Patrick Neven, MD, PhD,Yen-Shen Lu,Aditya Bardia, MD, MPH, FASCO,Giuseppe Curigliano,Virginia Kaklamani, MD, DSc,Pedram Razavi,Yoon Sim Yap,Fei Su,Estelle Roux,Kristyn Pantoja,Jiwen Wu,Agnes Lteif,Dejan Juric
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study
|
Keywords ADC Dato-DXd mechanism of action response resistance NSCLC TROP2 internalization Introduction In 2022, lung cancer was the most frequently diagnosed cancer, with about 2.5 million new cases, and the leading cause of cancer death, with 1.8 million deaths worldwide.1 Several targeting therapies have been developed and approved over the past years for the treatment of metastatic lung cancer, particularly for non-small cell lung cancer (NSCLC); however, only 35%–40% of patients with...
By David Planchard, Nathalie Cozic, Maria Fernanda Mosele, Noemie Corcos, Loic Le Bescond, Yoann Pradat, Maria Rosa Ghigna, Ghada Nachabeh, Alexia Alfaro, Cyril Catelain, Bastien Job, Fathia Mami-Chouaib, Severine Badel, Stephanie Corgnac, Françoise Farace, Marianne Oulhen, Patricia L. Kannouche, Nathalie Droin, Marie Wislez, Christos Chouaid, Hubert Curcio, Sophie Cousin Verified, Celine Mascaux, Jacques Cadranel, Margaux Geier, Rasha Cheikh-Hussin, Pierre Guyader, Nicholas Signolle, Karine Godefroy, Hugues Talbot, Maria Vakalopoulou, Stergios Christodoulidis, Elsa Bernard, Yves Akoli Koudou, Valerie Camara, Abdelhafidh Belarkemi, alexis klein, Jean Philippe Morretton, Philip East, Rachel Chiaverelli, Ricardo Zwirtes, Stefan Michiels, Fabrice Barlesi, Fabrice André, Guillaume Montagnac, Barbara Pistilli
|
Cell Press
Verified
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver Advances in diagnostic technologies and a deeper understanding of cancer biology have unlocked new opportunities for anticancer therapies in recent years. To sustain momentum, the global cancer community must unite to find strategies to optimise the drug development journey.
Novae: a graph-based foundation model for spatial transcriptomics data - Nature Methods
Abstract Spatial transcriptomics is advancing molecular biology by providing high-resolution insights into gene expression within the spatial context of tissues. This context is essential for identifying spatial domains, enabling the understanding of microenvironment organizations and their implications for tissue function and disease progression.
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study - British Journal of Cancer
Abstract Work-related determinants of return to work (RTW) after breast cancer (BC) have been poorly studied. We analysed data from 2095 patients with primary BC enrolled in the French multi-center prospective cohort CANTO between 2012 and 2018. We investigated the association between administrative, physical and psychosocial working conditions and RTW two years after diagnosis using Poisson regression with robust variance.
Optimising cancer care for individual patients is key to improving outcomes for all
An ESMO roadmap addresses how the new challenges in oncology can be transformed into opportunities for the benefits of oncology professionals and patients with cancer This year, ESMO turns 50. Fifty years of education, science dissemination and collaboration; of relentless commitment to improving cancer care; of evolving alongside a field that has transformed beyond recognition in the past decade alone. The pace of change in oncology demands more than reflection: it calls for renewal.
Le complexe sportif Maurice-chevalier va être inauguré samedi
Fabrice André (CLP) Après 17 mois de travaux qui ont permis d’allier performance énergétique et modernisation des espaces, le principal équipement sportif charnaysien, théâtre des exploits des Pinkies, va être inauguré samedi au cours d’une journée où vont se succéder les animations. Un an, quatre mois et vingt-six jours. C’est ce qu’auront dû patienter les Pinkies pour disputer un nouveau match dans leur chaudron.
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomar Original
Abstracts Identifying molecular alterations specific to advanced lung adenocarcinomas could provide insights into tumour progression and dissemination mechanisms. We analysed tumour samples, either from locoregional lesions or distant metastases, from patients with advanced lung adenocarcinoma from the SAFIR02-Lung trial by targeted sequencing of 45 cancer genes and comparative genomic hybridisation array and compared them to early tumours samples from The Cancer Genome Atlas.
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial - Nature Medicine
|
Abstract Antibody–drug conjugates have shown impressive clinical outcomes, particularly in metastatic breast cancer, but biomarkers to predict response and resistance remain unidentified. Here we report the results of ICARUS-BREAST01, a phase 2 study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan (HER3-DXd), in patients with HR+HER2− metastatic breast cancer, who previously progressed on CDK4/6 inhibitors and one line of chemotherapy.
By Barbara Pistilli, Fernanda Mosele, Magali Lacroix-Triki, Bastien Job, Fathia Mami-Chouaib, Patricia L. Kannouche, Nathalie Droin, Véronique D’Hondt, Thomas Bachelot, Elise Deluche, Stergios Christodoulidis, Fumitaka Suto, Stefan Michiels, Fabrice André, Françoise Farace, Jean Sebastien Frenel, Pierre Guyader, Hugues Talbot
|
Nature
Verified
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial - Nature Cancer
Abstract Immune checkpoint inhibitors improve the treatment of many solid tumors and have shown encouraging results in advanced squamous cell carcinoma (SCC), yet only a minority of patients respond to immune checkpoint inhibitor monotherapy. We conducted the PEVOsq trial, an open-label, nonrandomized, multicenter, basket phase 2 trial to evaluate the combination of pembrolizumab and vorinostat in recurrent/metastatic SCC of various origins.
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature | British Journal of Cancer
Abstract Treatment of advanced estrogen receptor-positive HER-2-negative breast cancer is based on hormonal therapy with aromatase inhibitors for postmenopausal women. However, acquired endocrine resistance is unavoidable at some point in the advanced or metastatic stage, and its underlying molecular mechanisms remain to be fully elucidated.
TGB : les Tarbaises y ont longtemps cru face à Charnay, mais en vain
Vraiment pas verni ! Après avoir perdu d’un point face à Bourges samedi dernier, Tarbes échoue encore d’un rien. Cette fois de deux unités à Charnay qui confirme ainsi son excellente saison. D’ailleurs, les protégées de François Gomez étaient cueillies à froid dès l’entame. Notamment par Shakayla Thomas qui marquait les 10 premiers points charnaysiens. Ce qui obligeait le coach tarbais à prendre rapidement un premier temps-mort (6-1, 3e). Mais l’intérieure américaine continuait son festival.
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial - Nature Medicine
Abstract Addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer remains unclear.
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer - Nature Communications
Correction to: Nature Communications https://doi.org/10.1038/s41467-024-52915-0, published online 4 October 2024 In this article the author’s name Naoual Menssouri was incorrectly written as Naoual Mensourri. The original article has been corrected.
The genomic and transcriptomic landscape of metastastic urothelial cancer - Nature Communications
Abstract Metastatic urothelial carcinoma (mUC) is a lethal cancer, with limited therapeutic options. Large-scale studies in early settings provided critical insights into the genomic and transcriptomic characteristics of non-metastatic UC. The genomic landscape of mUC remains however unclear. Using Whole Exome (WES) and mRNA sequencing (RNA-seq) performed on metastatic biopsies from 111 patients, we show that driver genomic alterations from mUC were comparable to primary UC (TCGA data).
Novae: a graph-based foundation model for spatial transcriptomics data
Abstract Spatial transcriptomics is advancing molecular biology by providing high-resolution insights into gene expression within the spatial context of tissues. This context is essential for identifying spatial domains, enabling the understanding of micro-environment organizations and their implications for tissue function and disease progression.
New clinical trials in CUP and a novel paradigm in cancer classification - Nature Reviews Clinical Oncology
Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors - British Journal of Cancer Original
Abstract Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identified metastasis-associated CNAs both in metastatic breast cancers (mBCs) and early breast cancers (eBCs). Single-nucleotide polymorphism (SNP)-array was performed on 926 biopsies from mBC patients, enrolled in SAFIR02-BREAST prospective trial.
Sopa: a technology-invariant pipeline for analyses of image-based spatial omics - Nature Communications
Abstract Spatial omics data allow in-depth analysis of tissue architectures, opening new opportunities for biological discovery. In particular, imaging techniques offer single-cell resolutions, providing essential insights into cellular organizations and dynamics. Yet, the complexity of such data presents analytical challenges and demands substantial computing resources.
Embracing cancer complexity: Hallmarks of systemic disease
|
PerspectiveVolume 187, Issue 7p1589-1616 1The Francis Crick Institute, London, UK 2Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK 3INSERM U981, Gustave Roussy, Villejuif, France 4AstraZeneca, Cambridge, UK 5Department of Medical Oncology, Gustave Roussy, Villejuif, France 6Paris Saclay University, Kremlin-Bicetre, France 7Laboratory of Integrative Systems Physiology, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland...
By Charles Swanton, Elsa Bernard, Chris Abbosh, Fabrice André, Johan Auwerx, Allan Balmain, Dafna Bar-Sagi, René Bernards, Susan Bullman, James DeGregori, Catherine Elliott, Ayelet Erez, Gerard Evan, Mark A. Febbraio, Andres Hidalgo, Mariam Jamal-Hanjani, Johanna A. Joyce, Matthew G. Kaiser, Katja A. Lamia, Jason W. Locasale, Sherene Loi, Ilaria Malanchi, Miriam Merad, Kathryn Musgrave, Ketan Patel, Sergio A Quezada, Jennifer Wargo, Ashani T Weeraratna, Eileen White, Frank Winkler, John Wood, Karen Vousden, Douglas Hanahan
|
Cell Press
Verified
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane - British Journal of Cancer
Abstract To identify patients most likely to respond to everolimus, a mammalian target of rapamycin (mTOR) inhibitor, a prospective biomarker study was conducted in hormone receptor-positive endocrine-resistant metastatic breast cancer patients treated with exemestane-everolimus therapy. Metastatic tumor biopsies were processed for immunohistochemical staining (p4EBP1, PTEN, pAKT, LKB1, and pS6K). ESR1, PIK3CA and AKT1 gene mutations were detected by NGS.
Charnay-les-Macon. [DIAPORAMA] Un ambiente de locura por la victoria de los Pinkies ante Chartres
En un Cosec en ebullición, los Pinkies de Charnay Basket Bourgogne Sud se impulsaron idealmente hacia un segundo título de campeón de la Ligue 2 francesa al ganar el partido de ida 80-69 contra Chartres, Mal embarcado por un tiempo contando 10 puntos por detrás (35-45, 22 ), los jugadores de Stéphane Leite lograron revertir la tendencia con la ayuda de sus fanáticos enfurecidos. Par Fabrice André (CLP) – 11:09 | actualizado a las 11:24
Bodywide ecological interventions on cancer - Nature Medicine
Abstract Historically, cancer research and therapy have focused on malignant cells and their tumor microenvironment. However, the vascular, lymphatic and nervous systems establish long-range communication between the tumor and the host.
Palbociclib fails to benefit breast cancer subgroup, yielding lessons for future research
Source/Disclosures Source: DeMichele A, et al. Adjuvant palbociclib for ER+ breast cancer (PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort. Presented at: ASCO Plenary Series; Oct. 18, 2022. Disclosures: DeMichele reports a consultant/advisory role with Pfizer and institutional research funding from Calithera Biosciences, Genentech, Novartis and Pfizer. Please see the abstract for all other researchers’ relevant financial disclosures.
ESMO’s new focus on cancer prevention
Publish date: October 5, 2022 This transcript has been edited for clarity. John Whyte, MD: Welcome, everyone. I’m Dr John Whyte. I’m the chief medical officer at WebMD, and I’m joined today by Fabrice André. He is the chair of the scientific committee at the European Society for Medical Oncology, where we are today in Paris, France. Bonjour, Fabrice. So, remind our viewers: What is ESMO? What does it do? And why is it so important?
ESMO's New Focus on Cancer Prevention
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Perspective > Medscape > ESMO 2022 This transcript has been edited for clarity. John Whyte, MD: Welcome, everyone. I'm Dr John Whyte. I'm the chief medical officer at WebMD, and I'm joined today by Fabrice André.
Genomics to select treatment for patients with metastatic breast cancer - Nature
Abstract Cancer progression is driven in part by genomic alterations1. The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations2, leading to the concept that generation of genomic profiling in patients with cancer could allow the selection of effective therapies3,4. Although DNA sequencing has been implemented in practice, it remains unclear how to use its results.
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A
Since the 2016 guidelines on biomarkers for patients with early-stage breast cancer, new data have been reported that offer additional guidance on genomic testing (Oncotype Dx 21-gene Recurrence Score [RS], MammaPrint, Prosigna, EndoPredict, and Breast Cancer Index [BCI]) to inform adjuvant endocrine and chemotherapy use, on the basis of patient age and number of involved axillary lymph nodes.1 The goal of the current guidelines is to update endocrine and chemotherapy recommendations in...
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A
Enter words / phrases / DOI / ISBN / authors / keywords / etc.
Impact of CDK4/6 Inhibitors on the Treatment Landscape
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Even today, the primary aim of treating patients with metastatic breast cancer remains to stabilise disease while maintaining the patient’s quality of life. However, the management of HR+/HER2- metastatic breast cancer has seen meaningful improvements in survival with the introduction of novel systemic therapies.
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
THE BOTTOM LINE Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Guideline Questions For patients with early-stage ER-positive, HER2-negative breast cancer, which biomarkers should be used to guide decisions on adjuvant endocrine and chemotherapy for a newly diagnosed cancer or in the extended setting?
Delivering precision oncology to patients with cancer - Nature Medicine
Abstract With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients.
Highlights • Drug-related interstitial lung disease (ILD)/pneumonitis diagnosis is challenging. • Careful monitoring, prompt diagnosis, and appropriate management are important. • Most events are low grade and can be managed safely. • Education is critical to ensure potential ILD/pneumonitis is proactively identified. • We suggest using a multidisciplinary approach. Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting human epidermal growth factor receptor 2.
Precision medicine interpreted with ‘right tools’ beneficial in metastatic breast cancer
December 07, 2021 2 min read Save Perspective from Source/Disclosures Published by: Source: André F, et al. Abstract GS1-10. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio. Disclosures: Fondation ARC, Breast Cancer Research Foundation and Agence Nationale de la Recherche supported this study. André reports grants from or advisory board/speaker honoraria to his institution from AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer and Roche.
Highlights • Everolimus and alpelisib are synergistic in preclinical models. • The pharmacokinetics of everolimus was unchanged in the presence of alpelisib. • The combination of alpelisib and everolimus was active in advanced solid tumors.
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Reviews Mihaela Aldea, Fabrice Andre, Aurelien Marabelle, Semih Dogan, Fabrice Barlesi and Jean-Charles Soria DOI: 10.1158/2159-8290.CD-20-1638 Published April 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Abstract The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not progress after six to eight cycles of chemotherapy. Patients (n = 199) were randomized to either durvalumab (10 mg kg−1 every 2 weeks) or maintenance chemotherapy.
Does academic research really need so much administrative work?
Research According to Fabrice André, Director of the Research Division at Institut Gustave Roussy, Villejuif, France, administrative work occupies more than half of the working time of academic researchers, discouraging young talent from moving into a career in independent research. Prof. Fabrice André Academic research in oncology is declining and the bureaucratic burden is a major contributory factor.
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
Abstract Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening and 31 (17.4%) died.
A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer
Expand allCollapse all A central strategy for healthcare surge control would be to provide remote effective monitoring of patients with Covid-19 and their follow-up. Telemedicine not only allows patients to be carefully screened but also enables a patient-centred system and being conducive to self-quarantine. In addition, patients, clinicians and the community are protected from exposure [1x[1]Hollander, J.E. and Carr, B. Virtually perfect? telemedicine for covid-19. NEJM.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
1. Finn RS Martin M Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016; 375: 1925-1936 2. Hortobagyi GN Stemmer SM Burris HA et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016; 375: 1738-1748 3. Goetz MP Toi M Campone M et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017; 35: 3638-3646 4. Turner NC Ro J André F et al. Palbociclib in hormone-receptor-positive advanced breast cancer.
Securing the future of the clinician-scientist
By integrating discovery science with clinical practice and therapeutic intervention, clinician-scientists fulfil a unique role in cancer research. However, their numbers are in decline, which is creating the need for flexible training and research opportunities to ensure their future. Fig. 1: Core components of flexible clinician-scientist training programs, as exemplified by CRUK’s Clinical Academic Training Program Awards. References 1. Jain, M. K. et al. N. Engl. J. Med. 381, 399–402 (2019). 2.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary
The ASCO Clinical Practice Guideline on the use of biomarkers to guide adjuvant therapy for early-stage invasive breast cancer was most recently published in February 2016.1 ASCO Guidelines are updated at regular intervals; however, there may be new evidence that potentially changes a recommendation and becomes available between scheduled updates. ASCO uses a signals approach to facilitate guideline updating.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx | Journal of Clinical Oncology
The ASCO Clinical Practice Guideline on the use of biomarkers to guide adjuvant therapy for early-stage invasive breast cancer was most recently published in February 2016.1 ASCO guidelines are updated at regular intervals; however, there may be new evidence that potentially changes a recommendation and becomes available between scheduled updates. ASCO uses a signals approach to facilitate guideline updating.
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
Metrics Downloaded 0 times History Received 7 February 2019 Accepted 19 March 2019 Published online 12 April 2019 Information © 2019 Future Medicine Ltd KeywordsAcknowledgements The authors thank the patients participating in the trial and their families, the investigators and staff at participating centers, the independent Data Monitoring Committee and the study team at F Hoffmann-La Roche Ltd.
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies - European Journal of Cancer
Publication HistoryPublished online: October 19, 2017Accepted: September 8, 2017; Received: August 1, 2017;
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Fabrice
Contact Fabrice, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack